Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD.

We came across a bullish thesis on Boston Scientific Corporation (BSX) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific Corporation (BSX)’s ...

The drug-eluting stent market is anticipated to grow at a CAGR of 8.20% from US$11.499 billion in 2025 to US$17.049 billion ...

R3 Vascular announced that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting ...

CAD continues to be the most common cause of morbidity and mortality in the western world. A well known cause of CAD is atherosclerosis. [4] Although coronary artery bypass graft surgery has been ...

Discover how IVBT impacts long-term outcomes in complex in-stent restenosis—read the full report for key clinical insights.

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial ...

The first drug-eluting stents (DESs) were approved by the FDA in 2003, after they were shown to significantly reduce rates of restenosis and repeat revascularization, when compared with bare-metal ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

We came across a bullish thesis on Boston Scientific Corporation (BSX ... steerable catheters to its transformative Taxus drug-eluting stent, BSX has consistently pushed the envelope in medical ...